Table 2. Detailed RAL-based regimen backbones.
| cART-naïve women, n | 16 | |
| NRTI | 14 (88%) | |
| FTC/TDF | Emtricitabine/tenofovir disoproxil fumarate | 8 (50%) |
| AZT/3TC | Zidovudine/lamivudine | 6 (38%) |
| bPI | 13 (81%) | |
| LPV/r | Lopinavir/ritonavir | 8 (50%) |
| DRV/r | Darunavir/ritonavir | 4 (25%) |
| ATZ/r | Atazanavir/ritonavir | 1 (6%) |
| cART-experienced women, n | 78 | |
| NRTI | 70 (90%) | |
| FTC/TDF | Emtricitabine/tenofovir disoproxil fumarate | 34 (44%) |
| ABC/3TC | Abacavir/lamivudine | 14 (18%) |
| AZT/3TC | Zidovudine/lamivudine | 7 (9%) |
| ABC | Abacavir | 7 (9%) |
| TDF | Tenofovir disoproxil fumarate | 5 (6%) |
| ZDV | Zidovudine | 2 (3%) |
| 3TC | Lamivudine | 1 (1%) |
| bPI | 54 (69%) | |
| DRV/r | Darunavir/ritonavir | 35 (45%) |
| ATZ/r | Atazanavir/ritonavir | 8 (10%) |
| LPV/r | Lopinavir/ritonavir | 9 (12%) |
| SQV/r | Saquinavir/ritonavir | 1 (1%) |
| FPV/r | Fosamprenavir/ritonavir | 1 (1%) |
| NNRTI | 4 (5%) | |
| ETR | Etranvirine | 3 (4%) |
| NVP | Nevirapine | 1 (1%) |
| CCR5 antagonist | 3 (4%) | |
| MVC | Maraviroc | 3 (4%) |
cART, combined Antiretroviral Therapy; NRTI, Nucleoside Reverse Transcriptase Inhibitor; NNRTI, Non-Nucleoside Reverse Transcriptase Inhibitor; bPI, boosted Protease Inhibitor.